Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 14/20 | 0.52 |
| ▸ | JAK2 | O60674 | 3/20 | 0.41 |
| ▸ | JAK3 | P52333 | 3/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20157643 | 0.90 | GRIN1 (0.46) | USP1JAK2JAK3ADORA3ALDH1A1 | |
| SCHEMBL20157446 | 0.87 | USP1 (0.57) | USP1JAK2JAK3ADORA3KDM4E | |
| SCHEMBL20157644 | 0.85 | USP1 (0.45) | USP1ADORA3 | |
| SCHEMBL20157768 | 0.85 | TLR7 (0.45) | USP1ADORA3 | |
| SCHEMBL20157335 | 0.85 | USP1 (0.42) | USP1ADORA3 | |
| SCHEMBL20157801 | 0.84 | USP1 (0.46) | USP1ADORA3 | |
| SCHEMBL20157433 | 0.80 | TLR7 (0.46) | USP1ADORA3 | |
| SCHEMBL20157161 | 0.80 | TLR7 (0.46) | USP1ADORA3 | |
| SCHEMBL20157637 | 0.79 | USP1 (0.40) | USP1ADORA3 | |
| SCHEMBL18866310 | 0.78 | USP1 (0.62) | USP1JAK2JAK3ADORA3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084818-B2 | Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use | HEPO PHARMACEUTICAL CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| US-20200062758-A1 | Nitrogen-Containing Heterocyclic Compound, Preparation Method, Intermediate, Pharmaceutical Composition and use | HEPO PHARMACEUTICAL CO., LTD. (CN) | 2020-02-27 | — | — | US | disclosed |
| EP-3539963-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | Livo (Shanghai) Pharmaceutical Co., Ltd (CN) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018086593-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | 礼沃（上海）医药科技有限公司 | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084818-B2 | Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use | TLR7, TLR9, TLR4 | USP1 3017/4885JAK2 140/4885JAK3 577/4885 |
| US-20200062758-A1 | Nitrogen-Containing Heterocyclic Compound, Preparation Method, Intermediate, Pharmaceutical Composition and use | TLR7, TLR9, NOD1 | USP1 2778/4885JAK2 300/4885JAK3 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.